<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04593459</url>
  </required_header>
  <id_info>
    <org_study_id>160120200001</org_study_id>
    <secondary_id>2020-000228-20</secondary_id>
    <nct_id>NCT04593459</nct_id>
  </id_info>
  <brief_title>Probiotic Intervention in PCOS</brief_title>
  <acronym>ProPCO-RCT</acronym>
  <official_title>Probiotic Dietary Intervention in Polycystic Ovary Syndrome (PCOS) - A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut AllergoSan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Winclove Probiotics</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of Graz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators are conducting a double-blinded randomized controlled trial to determine&#xD;
      whether a probiotic mixture is effective in reducing PCOS-related symptoms. For this purpose,&#xD;
      180 participants will be recruited in three intervention arms (Probiotic, Placebo and&#xD;
      Metformin), with 60 participants per arm. The intervention period will last 6 months, with&#xD;
      extensive medical history, blood work, urine and stool analysis at the beginning and the&#xD;
      conclusion of the trial.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 3, 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Probiotic vs placebo (double-blinded) vs metformin (open-label)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Only the probiotic and placebo are blinded, metformin is an open intervention arm</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Free testosterone</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in free testosterone levels [pg/ml] in serum after intervention</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anti-Müllerian hormone (AMH)</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in AMH levels in serum after intervention [ng/ml]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Androstenedione</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in androstenedione levels in serum after intervention [ng/ml]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dehydroepiandrosterone-sulphate (DHEA-S)</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in DHEA-S levels in serum after intervention [µg/ml]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>17-Hydroxyprogesterone (17-OH-progesterone)</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in 17-OH-progesterone levels in serum after intervention [ng/ml]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>17-OH-estradiol</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in 17-OH-estradiol levels in serum after intervention [ng/ml]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total testosterone</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in total testosterone levels in serum after intervention [ng/ml]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>25-OH-cholecalciferol</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in 25-OH-cholecalciferol levels in serum after intervention [ng/ml]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Luteinizing hormone (LH), Follicle-stimulating hormone (FSH)</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in LH and FSH levels in serum after intervention [mU/ml]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LH to FSH ratio</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in LH to FSH ratio after intervention [1]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in insulin levels in serum as measured with a two-hour oral glucose tolerance test (75 mg glucose in 300 ml water, blood draws at 0 minutes, 30 min, 60 min and 120 min) [mU/l]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in glucose levels in sodium-fluoride plasma as measured with a two-hour oral glucose tolerance test (75 mg glucose in 300 ml water, blood draws at 0 minutes, 30 min, 60 min and 120 min) [mg/dl]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Homeostasis Model Assessment for Insulin Resistance (HOMA-IR) index</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in HOMA-IR index (fasting insulin [mU/l] * fasting glucose [mg/dl]/405) after intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose mean</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in mean glucose levels (measured with oral glucose tolerance test with the formula g=(glucose0 + 2*glucose30 + 3*glucose60 + 2*glucose120)/8 [mg/dl]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin mean</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in mean insulin levels (measured with oral glucose tolerance test with the formula i=(insulin0 + 2*insulin30 + 3*insulin0 + 2*insulin120)/8 [mU/l]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Matsuda index</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in matsuda index after intervention measured with the formula M=10000/squareroot(glucose0 * insulin0 * glucose mean (see outcome 14) * insulin mean (see outcome 15))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hirsutism</measure>
    <time_frame>6 months</time_frame>
    <description>measured by modified Ferriman-Gallwey-score (mFG-score), ranging from 0 to 36, with 0 being the best possible value and 36 the worst</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body-mass-index (BMI)</measure>
    <time_frame>6 months</time_frame>
    <description>BMI measured with the formula BMI=weight [kg]/height² [m]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>waist-to-hip ratio</measure>
    <time_frame>6 months</time_frame>
    <description>Calculated with the formula: waist circumference/hip circumference [1]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sucrose-lactulose-mannitol test</measure>
    <time_frame>6 months</time_frame>
    <description>Functional gut permeability test consisting of ingesting 20 g sucrose, 5 g mannitol and 10 g lactulose in 100 ml water solution. Measurement of those three component concentrations in urine collected for 5 hours after solution ingestion by the participants. Lactulose to mannitol ratio may be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diaminooxidase</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in serum diaminooxidase levels after intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool and serum zonulin</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in stool and serum zonulin levels after intervention [ng/ml]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipopolysaccharide</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in lipopolysaccharide levels after intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Soluble cluster of differentiation (sCD14)</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in sCD14 levels in serum after intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calprotectin</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in stool calprotectin levels after intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bacterial DNA</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in bacterial DNA amounts in serum after intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gut lumen and mucosa microbiome composition and metagenomic profile</measure>
    <time_frame>6 months</time_frame>
    <description>Measured from stool samples via 16S-RNA gene sequencing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phytoestrogen production</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in daidzein and equol concentrations after intervention [ng/ml] measured in urine samples of participants after ingestion of soy milk</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Equol producer status</measure>
    <time_frame>6 months</time_frame>
    <description>Equol producer status as determined by the decadic logarithm of the equol/daidzein ratio [1]: A value above -0.5 is defined as an equol producer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QOL)</measure>
    <time_frame>6 months</time_frame>
    <description>QOL assessed by General Depression Scale (German: Allgemeine Depressionsskala), German equivalent of the Depression Scale by the Center for Epidemiological Studies (CES-D). The scale ranges from 0 to 60, with 0 being the best possible score and 60 the worst.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QOL</measure>
    <time_frame>6 months</time_frame>
    <description>QOL assessed by Beck´s Depression Inventory (BDI), a scale ranging from 0 to 63, with 0 being the best possible score and 63 the worst.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QOL</measure>
    <time_frame>6 months</time_frame>
    <description>Quality of Life measured by a PCOS questionnaire ranging from 0 to 156, with 0 being the best possible score and 156 the worst</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Lipid metabolism</measure>
    <time_frame>6 months</time_frame>
    <description>Low-density lipoproteins (LDL), high-density lipoproteins (HDL), lipoprotein a (LP(a)), triacylglycerols</description>
  </other_outcome>
  <other_outcome>
    <measure>Fluorescence-activated cell sorting (FACS) analysis</measure>
    <time_frame>6 months</time_frame>
    <description>B cell subtypes measured via FACS from whole blood</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>Probiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Probiotic product consisting of these 7 bacterial strains:&#xD;
Lactobacillus salivarius W57&#xD;
Lactobacillus casei W56&#xD;
Lactobacillus rhamnosus W71&#xD;
Lactococcus lactis W58&#xD;
Enterococcus faecium W54&#xD;
Lactobacillus plantarum W62&#xD;
Lactobacillus acidophilus W22&#xD;
Additional ingredients: Corn starch, maltodextrin, fructo-oligosaccharides, galacto-oligosaccharides, polydextrose, plant proteins, potassium chloride, magnesium sulfate, bacterial strains, manganese sulfate, lactose, 2000 IU vitamin D&#xD;
Participants ingest one sachet of powder (5 grams) in 200 ml of water per day for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Similar to probiotic product in optics and smell, less ingredients and no bacterial strains or vitamin D&#xD;
Ingredients: Corn starch, maltodextrin, potassium chloride, magnesium sulphate, manganese sulphate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metformin is an established drug for treating PCOS-related symptoms. The investigators are comparing the probiotic not only to a placebo group, but also to the benchmark treatment.&#xD;
Participants in the metformin arm will start treatment with 500 mg daily for the first week, then increasing the dose to 2x500 mg daily for the duration of the intervention.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotic</intervention_name>
    <description>See Arm description</description>
    <arm_group_label>Probiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin Hydrochloride</intervention_name>
    <description>See Arm description</description>
    <arm_group_label>Metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotic Placebo</intervention_name>
    <description>See Arm description</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Polycystic Ovary Syndrome diagnosed based on at least two out of three rotterdam&#xD;
             criteria: hyperandrogenism, polycystic ovarian morphology, oligo-/anovulation&#xD;
&#xD;
          -  signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Missing or withdrawn consent&#xD;
&#xD;
          -  Hyperandrogenism of a cause other than PCOS (Cushing´s syndrome, hyperprolactinemia,&#xD;
             adrenal tumours, congenital adrenal hyperplasia, rare genetic disorders)&#xD;
&#xD;
          -  Pregnancy or nursing period (first 6 months after giving birth)&#xD;
&#xD;
          -  Soy or other allergies with respect to study procedures&#xD;
&#xD;
          -  Diabetes mellitus type 1&#xD;
&#xD;
          -  Chronic inflammatory bowel disease, history of cancer in the gastrointestinal tract or&#xD;
             acute gastrointestinal infection&#xD;
&#xD;
          -  Any malignancies that required treatment within the last 3 years prior to study&#xD;
             procedures&#xD;
&#xD;
          -  Any other chronic disease requiring medical check-ups or hospital treatments at least&#xD;
             once every three months (exception: diabetes mellitus type 2)&#xD;
&#xD;
          -  Major surgery in the gastrointestinal tract (e.g. colectomy, gut segment excision with&#xD;
             stoma surgery, Whipple´s surgery.) Surgical removal of the appendix and/or the gall&#xD;
             bladder is NOT considered major surgery.&#xD;
&#xD;
          -  Therapy with antidiabetic drugs (metformin, sulfonylureas, dipeptidyl peptidase 4&#xD;
             (DPP-4) inhibitors, Glucagon-like peptide 1 (GLP-1) analogs,&#xD;
             sodium-glucose-cotransporter 2 (SGLT-2) inhibitors, insulin variants) within the last&#xD;
             six months prior to study procedures&#xD;
&#xD;
          -  Therapy with proton pump inhibitors within the last six months prior to study&#xD;
             procedures&#xD;
&#xD;
          -  Therapy with hormonal contraceptives or systemic (oral) intake of steroids within the&#xD;
             last six months prior to study procedures&#xD;
&#xD;
          -  Oral or intravenous therapy with antibiotics less than three months before the onset&#xD;
             of study procedures&#xD;
&#xD;
          -  Alcohol and/or drug abuse&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara Obermayer-Pietsch, Prof. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Graz, Division of Endocrinology and Diabetology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Valentin Borzan, MD</last_name>
    <phone>0043-316-385</phone>
    <phone_ext>14290</phone_ext>
    <email>valentin.borzan@medunigraz.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Barbara Obermayer-Pietsch, Prof. MD</last_name>
    <phone>0043-316-385</phone>
    <phone_ext>12383</phone_ext>
    <email>barbara.obermayer@medunigraz.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical University of Graz, Division of Endocrinology and Diabetology</name>
      <address>
        <city>Graz</city>
        <state>Styria</state>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Obermayer-Pietsch, Prof. MD</last_name>
      <phone>+43316-385-80253</phone>
      <email>barbara.obermayer@medunigraz.at</email>
    </contact>
    <contact_backup>
      <last_name>Valentin Borzan, MD</last_name>
      <phone>+43316-385-14290</phone>
      <email>valentin.borzan@medunigraz.at</email>
    </contact_backup>
    <investigator>
      <last_name>Barbara Obermayer-Pietsch, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Valentin Borzan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christian Trummer, PhD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stefan Pilz, Assoc.Prof., MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Verena Theiler-Schwetz, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claudia Stiegler, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marlene Pandis, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <reference>
    <citation>Lindheim L, Bashir M, Münzker J, Trummer C, Zachhuber V, Leber B, Horvath A, Pieber TR, Gorkiewicz G, Stadlbauer V, Obermayer-Pietsch B. Alterations in Gut Microbiome Composition and Barrier Function Are Associated with Reproductive and Metabolic Defects in Women with Polycystic Ovary Syndrome (PCOS): A Pilot Study. PLoS One. 2017 Jan 3;12(1):e0168390. doi: 10.1371/journal.pone.0168390. eCollection 2017.</citation>
    <PMID>28045919</PMID>
  </reference>
  <reference>
    <citation>Haudum C, Lindheim L, Ascani A, Trummer C, Horvath A, Münzker J, Obermayer-Pietsch B. Impact of Short-Term Isoflavone Intervention in Polycystic Ovary Syndrome (PCOS) Patients on Microbiota Composition and Metagenomics. Nutrients. 2020 Jun 1;12(6). pii: E1622. doi: 10.3390/nu12061622.</citation>
    <PMID>32492805</PMID>
  </reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 12, 2020</study_first_submitted>
  <study_first_submitted_qc>October 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2020</study_first_posted>
  <last_update_submitted>November 3, 2020</last_update_submitted>
  <last_update_submitted_qc>November 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Graz</investigator_affiliation>
    <investigator_full_name>Barbara Obermayer-Pietsch</investigator_full_name>
    <investigator_title>Professor, MD</investigator_title>
  </responsible_party>
  <keyword>PCOS</keyword>
  <keyword>Probiotic</keyword>
  <keyword>Metformin</keyword>
  <keyword>RCT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>For research and cooperation purposes, pseudonymized individual participant data may be shared with other researchers, the decision to do so lies with the principal investigator. In case of publication of our results in a peer-reviewed journal, all relevant data will be made publicly accessible without any personal information</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>to be determined</ipd_time_frame>
    <ipd_access_criteria>to be determined</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

